Benefits And Science

A preliminary randomized double-blind trial tested ultramicronized PEA at 600 mg twice daily for burning mouth syndrome. What it found, and how it compares.

Three randomized trials and a meta-analysis tested PEA plus luteolin for post-viral smell loss. All added it to olfactory training. What that means for you.

A randomized placebo-controlled trial tested PEA for seasonal hay fever. It missed its primary endpoint. What the subgroup and blood markers showed instead.

What randomized trials of PEA in major depression and acute mania found, how the inflammation hypothesis fits, and how to read the results overall.

PEA for interstitial cystitis and chronic pelvic pain: the six-month study, the responder analysis, and why short trials may miss a real effect.

Three trials tested PEA for exercise recovery and muscle soreness. One found a biomarker signal, one was clearly null, one was more complicated.

What the glaucoma trials on PEA measured, including the 2011 crossover study and normal-tension data, and how much eye pressure actually changed.

Veterinarians have used palmitoylethanolamide in dogs and cats for years. Here’s what a 2026 randomized trial and the older dermatology research actually show, and why giving your pet a human PEA capsule isn’t the same thing.

A case report on PEA for restless legs syndrome: what it documented, why the mechanism is plausible, and why one case is not evidence of effect.

What the 2018 trial of PEA in autism spectrum disorder actually tested, what the results showed, and what it does not establish for families.

PEA for dry eye disease: the pilot trial in glaucoma-related ocular surface disease, the preclinical data, and how eye drops differ from oral PEA.

What a 2025 randomized trial of PEA for menstrual pain tested, how large the effect was, and what the study does not tell you about dysmenorrhea.